Pain Medicine Doctors in Walnut Creek, CA Accepting Medicare

7 Pain Medicine doctors found. Showing 1 - 7

Kasra Amirdelfan, MD Pain Medicine - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 450 N Wiget Ln, Walnut Creek, CA 94598 Phone: 925-691-9806    Fax: 925-691-9807

Lawrence Weil, M.D Pain Medicine - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 450 N Wiget Ln, Walnut Creek, CA 94598 Phone: 925-691-9806    Fax: 925-691-9807

Syed Ejaz Naqvi, MD Pain Medicine - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 320 Lennon Ln, Walnut Creek, CA 94598 Phone: 925-906-2000

Jacob A Rosenberg, MD Pain Medicine - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 450 N Wiget Ln, Walnut Creek, CA 94598 Phone: 925-691-9806    Fax: 925-691-9807

Dr. Michael J Song, D.O. Pain Medicine - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 450 N Wiget Ln, Walnut Creek, CA 94598 Phone: 925-691-9806

Douglas Grant, MD Pain Medicine - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 450 N Wiget Ln, Walnut Creek, CA 94598 Phone: 925-691-9806    Fax: 925-691-9807

Marcelina Jasmine Silva, D.O. Pain Medicine - Interventional Pain Medicine Medicare: Medicare Enrolled Practice Location: 450 N Wiget Ln, Walnut Creek, CA 94598 Phone: 925-482-8151    Fax: 925-482-1166

News Archive

Tuberculosis control needs a complete and patient-centric solution

Whether it is mobile phone service or vacation travel, good businesses know that success depends on providing a complete and customer-centric solution. Should patients with tuberculosis not be offered a complete solution that is patient-centered? After all, millions are affected and a large market at the base-of-the-pyramid (BoP) remains unserved.

Programs known to reverse the negative effects of poverty are being widely neglected, shows report

The coronavirus (COVID-19) pandemic has caused widespread harm to the health and well-being of already vulnerable children and adolescents in the U.S., particularly those in low-income households and children of color.

Researchers propose new reforms to improve transparency of drug authorizations

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of COVID-19. On June 15, after a number of studies failed to find positive effects, the agency revoked this authorization.

SQI Diagnostics third quarter net loss increases to $2,691,000

SQI Diagnostics Inc., a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the third quarter ended June 30, 2011.

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.

Read more Medical News

› Verified 7 days ago